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Abstract
Introduction The ras pathway is essential for cell growth and
proliferation. The effects of R115777, a farnesyl transferase
inhibitor, were investigated in cancer cell lines expressing
varying levels of growth factor receptors and with differing ras
status. Effects on tumour xenografts and human ductal
carcinoma in situ (DCIS) of the breast in a xenograft mouse
model were also tested.
Method  In vitro, the concentrations required to reduce cell
numbers by 50% (50% inhibitory concentration) were
established (MDA-MB231, MCF-7, MCF-7/HER2-18, BT-474,
SK-BR3 and SKOV3). Human DCIS was implanted in nude
mice or, in separate experiments, cultured cells were injected
(MDA-MB231, MCF-7/HER2-18, SKOV3) and allowed to form
tumours. Proliferation and apoptosis were determined by
immunohistochemistry in xenografts and cell tumours.
Results The 50% inhibitory concentrations varied a hundred-
fold, from 39 nmol/l (± 26 nmol/l) for SKBR3 to 5.9 µmol/l(± 0.8
µmol/l) for MDA-MB231. In MCF-7/HER2-18 and SKOV3 cells
the levels of tumour growth inhibition were approximately 85%
and 40%, respectively. There was a significant decrease in the
cell turnover index (CTI; proliferation/apoptosis). In MDA-MB
231 with activated k-ras no inhibition was observed. In treated
DCIS xenografts proliferation decreased and apoptosis
increased. The CTI ratio between the start and 1 and 2 weeks
of treatment were 1.99 and 1.50, respectively, for controls and
0.85 (P = 0.005) and 0.75 (P = 0.08) for treated xenografts.
Conclusion Treatment with the farnesyl transferase inhibitor
reduced cell growth in vitro and cell tumour growth in vivo. In
DCIS treatment resulted in a reduced CTI. R115777 is a
promising treatment for breast cancer but the relation between
effect and growth factor receptor and ras status has to be
established.
Introduction
RAS pathway activity is critical for tumour growth [1]. In breast
cancers, activity of the ras signalling pathway appears to be
increased chiefly via activation of wild-type ras proteins by
upstream growth factor receptors such as the epidermal
growth factor receptor and c-erbB-2 (HER2) [2,3]. Expression
of these receptors is increased in 30–40% of all breast can-
cers [4]; furthermore, over-expression is indicative of a more
aggressive phenotype [5,6].
Point mutations in ras genes result in over-activated ras pro-
teins. The incidence of ras mutations in human tumours overall
is about 30%, whereas the incidence of activating ras muta-
tions in breast cancers is low, at only a few percent [7-9]. The
ras pathway is activated by a variety of extracellullar factors
[10] and aberrant function of the ras signal transduction path-
way is thought to be common in breast cancer [2]. Preclinical
data have suggested that ras inhibition has an inhibitory effect
on growth in cell lines that express both mutated and wild-type
ras [11-13].
CTI = cell turnover index; DCIS = ductal carcinoma in situ; ER = oestrogen receptor; FCS = foetal calf serum; FTI = farnesyl transferase inhibitor; 
IC50 = 50% inhibitory concentration; PI3K = phosphatidylinositol 3-kinase; STI = signal transduction inhibitor.Breast Cancer Research    Vol 8 No 2    Wärnberg et al.
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The ras proteins play an important role in signal transduction
and cellular transformation [14]. To function in signal transduc-
tion and activation of downstream pathways ras must attach to
the plasma membrane where it can interact with membrane
receptors and downstream effectors such as RAF and phos-
phatidylinositol 3-kinase (PI3K). Activation of the RAF-MAPK
(mitogen-activated protein kinase) pathway stimulates prolifer-
ation in the cell, and activation of the PI3K-PKB (protein kinase
B)/Akt pathway is related to increased cell survival [15]. Ras is
synthesized as a pro-peptide (pro-ras). One way to target ras
activity is to inhibit the enzyme farnesyl transferase, which cat-
alyzes a major step in the modification of pro-ras. Farnesylation
makes the ras protein more hydrophobic, and therefore it
becomes possible for the protein to attach to the plasma mem-
brane [10]. Several different farnesyl transferase inhibitors
(FTIs) have been developed. The drug investigated in this
study (R115777) is an imidazole-based FTI that acts as a com-
petitive inhibitor of the carboxyl-terminal tetrapeptide CAAX of
ras [16-19].
In the present study we tested the effects of the FTI R115777
on growth of breast and ovarian cancer cell lines expressing
varying levels of HER2 and epidermal growth factor receptor
and with differing ras status, and on ductal carcinoma in situ
(DCIS) of the breast in a human xenograft model. Widespread
DCIS was previously used for implantation in experiments sim-
ilar to this study [20,21]. The take rate of DCIS xenografts has
been shown to be high; furthermore, DCIS express HER2 in
70% of high-grade DCIS lesions [22,23], which makes DCIS
suitable for studies targeting the ras pathway.
In this study we have shown that treatment with the FTI
R115777 reduced cell growth in vitro and cell tumour growth
in vivo. In human DCIS xenografts treatment resulted in a
reduced cell turnover index (CTI).
Materials and methods
Patients
Participants in this study were women who attended the
Nightingale Breast Screening Assessment Centre or the
Symptomatic Breast Clinic at the University Hospital of South
Manchester, UK during the period from April 2002 to April
2003. Women were included in the study if they had mammo-
grams showing widespread microcalcifications indicative of
DCIS, with or without an invasive component, and histopatho-
logical confirmation of the diagnosis by core biopsy before
surgery (n = 14). Written consent was obtained, and only
those women undergoing mastectomy were included. A con-
sultant breast pathologist subsequently reviewed all tissue
samples. Approval to remove tissue from pathological samples
in this study was granted by the South Manchester Research
Ethics Committee.
Animals
Athymic female nude mice (BALB/c nu/nu, aged 6–8 weeks)
were purchased and allowed to acclimatize for 1–2 weeks
before experiments were started. The mice were housed
under conventional conditions with a 12-hour cycle of light and
dark in filter top cages (n = 5–6/cage) and given free access
to normal feed, water and bedding during the experiments. All
care of the animals and surgical procedures were performed
in accordance with Home Office Regulations and the UK Sci-
entific Procedures Act (1986).
Treatment of ductal carcinoma in situ tissue samples and 
xenografts
A 1–2 cm3 specimen of breast tissue from the area with micro-
calcifications was taken at the time of surgery and handled as
described previously [20,21]. The specimen was dissected
into 2 × 2 × 1 mm pieces and a random collection of 5–10
pieces was withdrawn as day 0 samples and processed for
histology. The tissue was collected well away from any areas
showing signs of invasive cancer on the mammogram, and in
our day 0 xenografts we found no signs of invasive cancer. The
remaining xenografts were implanted into 5–30 mice, depend-
ing on tissue volume. Each mouse received tissue from one
patient only and implantation was completed within 90 min of
removal of the tissue from the patient. Eight xenografts (in
pairs) were implanted subcutaneously in four sites symmetri-
cally in the flanks. After 2 weeks one pair of xenografts was
removed and treatment was started (day 14). Another pair of
xenografts was removed after 7 days of treatment (day 21),
and the remaining xenografts were removed after 14 days of
treatment (day 28) at the end of the experiment. After retrieval,
the xenografts were immediately fixed in buffered formalin for
24 hours at 4°C and then stored in 70% ethanol before paraf-
fin embedding.
Treatment
Treatment with R115777 (50 mg/kg or 100 mg/kg; Johnson
and Johnson Pharmaceutical Research and Development,
Raritan, NJ, USA) or control vehicle (20% β-cyclodextrin) was
given as a gavage twice daily from Monday to Friday and once
daily during weekends. Treatment was given over 14 days in
the experiments with human DCIS. In the experiments with
implanted cell tumours the duration of treatment varied
between 8 and 29 days in different experiments, depending on
how fast the tumours grew. We chose the doses 50 mg/kg
and 100 mg/kg, based on data from previous experiments with
R115777 [12].
Ras activity in vitro and in vivo
Cell culture
The human breast cancer cell lines MDA-MB231, MCF-7,
MCF-7/HER2-18, BT-474 and SK-BR3 and the human ovar-
ian cancer cell line SKOV3 were obtained from the American
Type Culture Collection (Rockville, MA, USA) and grown and
subcultured according to their instructions. The breast cancerAvailable online http://breast-cancer-research.com/content/8/2/R21
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cell lines were chosen based on their different expression of
growth factor receptors, and the SKOV3 ovarian cell line was
used as a model for oestrogen receptor (ER) negative and
wild-type ras cancer. Data concerning growth factor expres-
sion, ER expression and ras protein status were collected from
the literature and are given in Table 1.
Assessment of cell growth in vitro
The effect of R115777 on cell growth was used to establish
the concentrations required to reduce cell numbers by 50%
(50% inhibitory concentration [IC50]). Cells were plated in 96-
well plates in growth medium containing 2–5% foetal calf
serum (FCS), and after 24 hours the medium was discarded
and replaced with medium containing varying concentrations
of R115777 (0, 1 nmol/l, 10 nmol/l, 100 nmol/l, 500 nmol/l, 1
µmol/l, 5 µmol/l and 10 µmol/l). The plated number of cells
and the concentration of FCS were established for each cell
line in separate experiments to find suboptimal growing condi-
tions for use in the following experiments with R115777.
Treatment was continued until untreated cells reached conflu-
ence. Estimation of cell number was done by means of the sul-
phorhodamine B colorimetric assay. Three separate
experiments were conducted for each cell line, in which each
concentration of R115777 was tested in quadruplicate.
Assessment of tumour growth in nude mice
Cells (2–4 × 106) in a 200 µl solution of growth medium con-
taining 10% FCS were injected subcutaneously into each
flank of each mouse and allowed to form tumours. In the exper-
iments involving the oestrogen-dependent MCF-7/HER2-18
cell line, oestrogen pellets (2 mg) were implanted subcutane-
ously at the base of the tail of the mice at the time of cell injec-
tion [24]. Treatment with R115777 50 mg/kg or 100 mg/kg or
control vehicle (20% β-cyclodextrin) was begun when meas-
urable tumours were formed in about 75% of injection sites.
Only tumours that were measurable at the start of treatment
were included in the analyses. Tumours were measured with a
calliper twice weekly and tumour volume was calculated using
the following formula: tumour volume = (width)2 × (length/2).
Each experiment was terminated and all tumours were
removed when any of the mice developed a tumour burden of
more than 1 cm3. Tumours were divided and processed for
immunohistochemistry or were stored in liquid nitrogen. The
growth inhibitory effect of R115777 was calculated using the
following formula: 1 - ([D - C]/[Bmedian - Amedian]) × 100%,
where D is the final tumour volume after R115777 treatment,
C is the tumour volume before R115777 treatment, B is the
median final tumour volume among control tumours after treat-
ment, and A is the median tumour volume among control
tumours before treatment. For each of the cell lines two sepa-
rate experiments were conducted and the median growth inhi-
bition among all R115777-treated tumours was calculated.
Assessment of proliferation index, apoptotic index and 
cell turnover index
Sections of DCIS xenografts and cell tumours were scored for
proliferation after Ki67 immunohistochemical staining (MIB-1;
Coulter-Immunotech, Luton, UK). At least 300 cells in the
xenografts and 1,000 cells in the cell tumours were counted at
a magnification of ×40. To assess apoptosis in the xenografts,
we sought morphological evidence of apoptosis using haema-
toxylin and eosin stained sections. In the cell tumours immuno-
histochemistry (TdT-mediated dUTP-fluorescence nick end
labelling) was used. At least 1,000 cells were counted at a
magnification of ×40. Proliferation and apoptotic indices were
both expressed as a percentage of apoptotic or stained cells.
The immunohistochemistry methodology and apoptotic scor-
ing was described previously [21,25-27]. A CTI (proliferation
index/apoptotic index) [28] was calculated for each individual
xenograft and cell tumour. All counting was performed without
knowledge of treatment group.
Table 1
Results from cell and cell tumour experiments
Cell line IC50 (mean ± SEM) Tumour growth inhibition in vivo 
by R115777
Ras statusa ERa EGFRa HER2a
50 mg/kg 100 mg/kg
SK-BR3 39.0 ± 25.8 nmol/l - - Wild-type - + ++
MCF-7 46.0 ± 5.0 nmol/l - - Wild-type, over-expression of n-ras ++ + (+)
MCF-7/HER2-18 60.3 ± 117 nmol/l 80.8% 95.9% Wild-type, over-expression of n-ras ++ + +++
BT474 195 ± 119 nmol/l - - Wild-type + - ++
SKOV3 2.7 ± 0.4 µmol/l 60.1% 20.4% Wild-type - ++ +++
MDA-MB231 5.9 ± 0.8 µmol/l -68.8% -91.2% Mutated k-ras - +++ +
The table shows the concentration of R115777 required to reduce cell numbers by 50% (50% inhibitory concentration [IC50]), inhibition by 
R115777 at two different doses in tumours grown in athymic mice, and receptor and ras status for the different cancer cell lines. aData collected 
from the literature [4,12,46]. EGFR, epidermal growth factor receptor; ER, oestrogen receptor; SEM, standard error of the mean.Breast Cancer Research    Vol 8 No 2    Wärnberg et al.
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Assessment of farnesyl transferase inhibition in vitro 
and in vivo
Western blots were performed on MCF-7 and MCF-7/HER2-
18 cells treated with different doses of R115777 and on MCF-
7/HER2-18 tumours from the in vivo experiments. Protein
extracts were prepared from cell pellets or tumours after thaw-
ing the cryopreserved samples and washing them with phos-
phate-buffered saline. The cells were lysed in ice-cold
radioimmunoprecipitation assay buffer (50 mmol/l Tris-HCl
[pH 7.5], 150 mmol/l NaCl, 0.1% Triton X-100, 0.5% deoxy-
cholate, 0.1 mmol/l ethyleneglycoltetracetic acid, and 0.1
mmol/l EDTA) with protease inhibitors for 5 minutes on ice.
The protein concentration of each lysate was quantified using
a colorimetric assay (BCA Protein Assay; Pierce, Rockford, IL,
USA) and 50 µg total protein was loaded on an 8% SDS poly-
acrylamide gel. The Western blots were transferred to polyvi-
nyledene difluoride membrane and probed with a mouse
monoclonal antibody against HDJ2 (KH2A5.6; NeoMarkers,
Fremont, CA, USA) [29]. Bound antibody was detected using
a horseradish peroxidase conjugated secondary antibody and
visualized by treating the membrane with enhanced chemilumi-
nescence reagents (Amersham Pharmacia Biotech Inc., Pis-
cataway, NJ, USA) and exposing it to film. Detection of an
unfarnesylated and a farnesylated band of the HDJ2 protein
represents conclusive evidence of farnesyl transferase inhibi-
tion.
Statistical analysis
The IC50s are presented as the mean value of three separate
experiments with the corresponding standard errors of the
mean. Tumour growth inhibition is given as a percentage. The
percentage with interquartile range is based on the median
growth inhibition among treated tumours relative to the median
control tumour growth. Statistical significance of tumour
growth inhibition was tested by comparing individual tumour
growth in cubic millimetres between treated and control
tumours using the Mann-Whitney U test.
Comparisons between the R115777 treated and control sam-
ples in the DCIS xenograft experiments were made 'within-
patient' using a repeated analysis of variance model with
patient and group (R155777 versus control) as factors. This
statistical model matched the R11577 and control readings
from mice transplanted from the same women. Data were
restricted to those mice with tissue from women with readings
available from both R115777 and control mice. Throughout
the analysis, 'mouse' was taken as the unit of analysis and only
data from mice with data from both day 14 and day 21 or day
28 were included, because we looked at change over time in
terms of proliferation, apoptosis and CTIs. Data are presented
as the geometric means with their 95% confidence intervals.
The significance level was set at 5% and all tests were two
Figure 1
Tumour growth inhibition Tumour growth inhibition. (a) Tumour growth inhibition in MCF-7/HER2-18 tumours grown in athymic mice treated with R115777 50 mg/kg or 100 
mg/kg. Median tumour volume in treated relative to control animals is given in cubic millimetres. (b) Tumour growth inhibition by R115777 in SKOV3 
tumours. (c) Tumour growth inhibition by R115777 in MDA-MB231 tumours.Available online http://breast-cancer-research.com/content/8/2/R21
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sided. Statistical analysis was performed using STATA soft-
ware (STATA Corporation, College Station, TX, USA).
Results
Cell growth
IC50 for R115777 varied a hundred-fold, from 39 nmol/l and
46 nmol/l for SK-BR3 and MCF-7 to 2.7 µmol/l and 5.9 µmol/
l for SKOV3 and MDA-MB231 cell lines, respectively, when
grown in vitro (Table 1). The cell line with the mutated k-ras,
namely MDA-MB231, had the highest IC50, whereas in the cell
lines with wild-type ras the drug was effective at lower doses.
In mice, growth of MCF-7/HER2-18 tumours was inhibited by
R115777 50 mg/kg (n = 19) and 100 mg/kg (n = 11) by
80.8% (interquartile range 56.4–99.0%; P  = 0.001) and
95.9% (68.2–110.1%; P  = 0.02), respectively, compared
with control tumours (n = 22; Figure 1a and Table 1). The pro-
liferation index was lower in the treated tumours; for R115777
50 mg/kg it was 69.6% (63.4–74.8%; P = 0.003) and for
R115777 100 mg/kg it was 65.5% (62.0–70.1%; P  <
0.0001) as compared with 77.7% for the control tumours
(74.4–81.1%; Table 2). The apoptotic index was higher in the
treated tumours; for R115777 50 mg/kg it was 1.5% (1.2–
1.6%; P = 0.04) and for R115777 100 mg/kg it was 1.6%
(1.4–1.9%; P = 0.003) as compared with 1.2% in the control
tumours (0.9–1.5%). The CTIs for tumours treated with
R115777 50 mg/kg and 100 mg/kg were 48.7 (41.6–57.4; P
= 0.0009) and 38.0 (30.1–43.3; P < 0.0001), respectively,
and these values were statistically significantly reduced as
compared with the CTI of 61.6 in controls (55.5–79.5; Table
2).
Growth of SKOV3 tumours was inhibited by R115777 50 mg/
kg (n = 30) and 100 mg/kg (n = 14) by 60.1% (32.3–83.9%;
P = 0.04) and 20.4% (-65.7 to +38.3%; P = 0.4), respec-
tively, as compared with that in control tumours (n = 14; Figure
1b and Table 1). The proliferation index was lower in treated
tumours; for R115777 50 mg/kg it was 34.1% (26.5–44.4%;
P = 0.009) and for R115777 100 mg/kg it was 40.1% (33.1–
44.0%; P = 0.08) as compared with 46.6% in the control
tumours (37.6–55.0%). The apoptotic index did not differ
between treated tumours; for R115777 50 mg/kg it was
0.49% (0.4–0.7%; P = 0.11), for R115777 100 mg/kg it was
0.48% (0.4–0.8%; P = 0.18) and it was 0.35% in the control
tumours (0.3–0.5%). The CTIs for tumours treated with
R115777 50 mg/kg and 100 mg/kg were 67.5 (45.6–96.1; P
= 0.004) and 81.0 (38.6–110.2; P  = 0.05), respectively;
these values were statistically significantly reduced as com-
pared with the CTI of 125.4 in controls (87.1–188.9; Table 2).
Growth of k-ras mutated MDA-MB231 tumours was not inhib-
ited by R115777 50 mg/kg (n = 25) and 100 mg/kg (n = 15).
Instead, the growth in the treated tumours was increased by
68.8% (13.8–284.1%; P = 0.08) and 91.2% (2.8–328.8%; P
= 0.09), respectively, relative to control tumours (n = 16; Fig-
ure 1c and Table 1). The proliferation index was higher,
although not statistically significantly higher, in the treated
tumours; for R115777 50 mg/kg it was 68.2% (63.3–71.5%;
Table 2
Apoptosis and proliferation in cell tumour experiments
Cell line Control Treated R115777
50 mg/kg 100 mg/kg
MCF-7/HER2-18
Ki67 (%) 77.7 (74.4–81.1) 69.6** (63.4–74.8) 65.5**** (62.0–70.1)
TUNEL (%) 1.2 (0.9–1.5) 1.5* (1.2–1.6) 1.6** (1.4–1.9)
CTI 61.6 (55.5–79.5). 48.7*** (41.6–57.4) 38.0**** (30.1–43.3)
SKOV3
Ki67 (%) 46.6 (32.0–63.8) 34.1** (20.3–57.2) 40.1 (26.6–48.8)
TUNEL (%) 0.35 (0.1–0.8) 0.49 (0.1–1.0) 0.48 (0.1–1.4)
CTI 125.4 (87.1–188.9). 67.5**(45.6–96.1) 81.0* (38.6–110.2)
MDA-MB231
Ki67 (%) 61.7 (54.1–74.6) 69.3 (56.1–78.0) 72.4* (43.8–83.1)
TUNEL (%) 0.55 (0.3–0.9) 0.45 (0.3–0.6) 0.31* (0.1–0.4)
CTI 106.0 (85.8–191.0). 180.1 (115.9–205.4) 180.8 (90.5–227.7)
Effect of R115777 on proliferation (Ki67), apoptosis (TdT-mediated dUTP-fluorescence nick end labelling [TUNEL]) and cell turnover index (CTI) 
in cell line tumours grown in athymic nude mice. Values are expressed as median values (interquartile range). *P < 0.05, **P < 0.01, ***P < 0.001, 
****P < 0.0001.Breast Cancer Research    Vol 8 No 2    Wärnberg et al.
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P = 0.24) and for R115777 100 mg/kg it was 72.4% (66.4–
78.4%; P = 0.06) as compared with 57.9% in the control
tumours (54.1–71.4%). The apoptotic index was similar in
treated and control tumours; for R115777 50 mg/kg it was
0.4% (0.3–0.6%; P = 0.98), for R115777 100 mg/kg it was
0.4% (0.3–0.7%; P = 0.75) and for controls it was 0.4% (0.3–
0.6%). The CTIs for tumours treated with R115777 50 mg/kg
and 100 mg/kg were 180.1 (115.9–205.4; P = 0.32) and
180.8 (90.5–227.7; P = 0.37), respectively, and the CTI for
controls was 106.0 (85.8–191.0; Table 2).
In the xenograft experiments no difference in body weight was
seen between R115777 and controls; neither was there any
difference in the number of deaths seen between treated and
control animals.
Ductal carcinoma in situ
Tissue from 14 women with widespread DCIS was implanted.
In four of the cases no DCIS was found in the day 0 xenografts
or in the implanted xenografts, and these women were
excluded from further analyses. The median age among the
remaining 10 women with implanted DCIS was 53 years
(range 39–72 years). Nine out of the 10 women had foci of
invasive cancer in their mastectomy specimen according to
the final histopathological report. Nine lesions were nuclear
grade III and the remaining lesions were nuclear grade II. The
grading was done on the in situ part only in lesions with inva-
sive cancer. Accordingly, the data presented on proliferation,
apoptosis and CTI are from the 10 experiments with implanted
DCIS. Four experiments were conducted with the dose
R115777 50 mg/kg and six with 100 mg/kg. Eight out of the
10 cases of DCIS were ER positive (for instance, >5% stained
cells). Seven of the cases were clinically regarded as positive
for HER2 (2+ or 3+) and three were regarded as negative (0
or 1+).
Fifty-four out of 80 (67.5%) day 0 xenografts contained ducts
with DCIS. The harvested xenograft pairs contained DCIS in
44.8% (493/1100). Accordingly, the overall take rate was cal-
culated at 66.4%.
The proliferation and apoptotic indices and CTI from the DCIS
experiments are presented in Table 3. There was decreased
proliferation in the xenografts treated with R115777. The
ratios of proliferation indices between day 14 and day 21 were
1.38 for controls (n  = 65) and 0.75 for treated (n  = 61)
xenografts, respectively (P = 0.04). The ratios between day 14
and day 28 were 1.22 for controls (n = 75) and 0.78 for
treated (n = 66) xenografts, respectively (P = 0.06).
Apoptosis increased in the treated DCIS xenografts. The
ratios between day 14 and day 28 were 0.83 for controls (n =
95) and 1.06 for treated (n = 104) xenografts, respectively (P
= 0.005).
Overall, CTI decreased in treated xenografts. The ratios of
CTIs between day 14 and day 21 were 1.99 for controls (n =
44) and 0.85 for treated (n = 49) xenografts, respectively (P =
0.005). The ratios between day 14 and day 28 were 1.50 for
controls (n = 67) and 0.75 for treated (n = 62) xenografts,
respectively (P = 0.08). The results of proliferation and apop-
tosis in the experiments with the different doses of R115777
pointed in the same direction, except for an unchanged apop-
totic index after 7 days of treatment in the lower dose group
(data not shown).
There was no statistically significant difference in body weight
loss/gain or number of deaths between treated and control
animals in the DCIS xenograft experiments.
Farnesyl transferase inhibition
In all MCF-7 and MCF-7/HER2-18 cell samples treated with
different doses of R115777 in vitro, an unfarnesylated ras
band was detected with Western blot technique. This unfar-
nesylated ras band was not detected in any of the untreated
cell samples (Figure 2a). The cell tumours chosen in this anal-
ysis were MCF-7/HER2-18 tumours showing good response
on R115777 treatment and MCF-7/HER2-18 control tumours
with uninhibited growth. This selection of tumours was made
in an attempt to establish proof of farnesyl tranferase inhibition
in vivo. In four out of five treated MCF-7/HER2-18 tumours an
unfarnesylated ras band was detected, whereas in six out of
Figure 2
Farnesyl transferase inhibition in vitro and in vivo Farnesyl transferase inhibition in vitro and in vivo. (a) Detection of an unfarnesylated and a farnesylated band of the HDJ2 protein by Western blot 
technique on cell pellets treated with different doses of R115777 and controls. All treated cell pellets exhibit a high proportion of unfarnesylated pro-
tein. (b) Detection of an unfarnesylated and a farnesylated band of the HDJ2 protein by Western blot technique on MCF-7/HER2-18 cell tumours 
treated with R115777 or control vehicle. Tumours were selected from those tumours treated with R115777 exhibiting a good response and control 
tumours with no response on tumour growth. In four out of five treated tumours an unfarnesylated protein was detected.Available online http://breast-cancer-research.com/content/8/2/R21
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six control tumours no unfarnesylated ras was detected (Fig-
ure 2b).
Discussion
In this study we demonstrated reduced tumour growth in vivo
and reduced cell growth in vitro in human cancer cell lines with
wild-type ras and varying levels of growth factor receptors,
when treated with the FTI R115777. We have shown that the
effect on growth is related to a reduced CTI in the cancer cell
lines tumours in vivo and that the CTI was statistically signifi-
cantly reduced in human DCIS treated by the FTI after 1 week.
The effect on the CTI was due to both an antiproliferative and
a pro-apoptotic effect.
To study the effect of an FTI, we conducted a series of exper-
iments: first, the in vitro studies on different human cancer cell
lines; second, in vivo studies of tumour growth inhibition in
selected cell lines; and, finally, studies of human DCIS
implanted directly from the operating theatre into nude mice in
a model earlier used in our department. The ras pathway is
activated by a variety of extracellullar factors, and aberrant
function of ras signal transduction is not only due to ras muta-
tions. We could not assess activation of the ras signalling
pathway, but chose to study the downstream effects of the
FTI, measured as change in apoptosis and proliferation. We
also tried to relate the effect of the FTI to growth factor recep-
tor status and ras status. Furthermore, by showing an unfar-
nesylated protein in treated cell pellets and cell line tumours,
we demonstrated the effect on farnesylation by the FTI
R115777.
Strikingly, we found an effect on proliferation and apoptosis
that was consistent in the in vivo studies of cell tumours
expressing wild-type ras (MCF-7/HER2-18 and SKOV3) and
in human DCIS. The results of growth inhibition in vitro were
in accordance with the in vivo results (for instance, the largest
effect on tumour growth in vivo was seen in the cell line with
the lowest IC50 in vitro). No antiproliferative effect and no pro-
apoptotic effect were seen in the k-ras mutated MDA-MB231
tumours treated with the FTI, and no tumour growth inhibition
resulting from treatment was observed in this cell line. The
MDA-MB231 cell line also had the highest IC50. Other FTIs
have been shown to inhibit both mutated and wild-type ras
[30,31], but a relative resistance to FTIs in k-ras mutated cell
lines has also been reported [32,33]. Although we were una-
ble to establish the ras status of the DCIS lesions in our human
DCIS xenograft experiments, the majority (70%) were HER2
positive and would be expected to have activated wild-type
ras. We found no areas of invasive breast cancer in our day 0
xenografts. However, if some mixture of invasive cancer cells
had occurred in the xenografts, then this should have been
evenly distributed between controls and treated animals,
therefore causing no bias.
The cell lines considered in our in vitro experiments were
selected to represent different expressions of growth factor
receptor and ERs. We were unable to detect a clear relation-
ship between any of the factors and the effect of the FTI. For
example, the IC50s in the MCF-7 and in the MCF-7/HER2-18
were not significantly different in the in vitro experiments. The
MCF-7/HER2-18 is a MCF-7 cell line with 45-fold over-
expression of the HER2 receptor caused by transfection with
full-length HER2 cDNA [34]. However, in an experiment simi-
lar to ours, in which cell line tumour growth inhibition was stud-
ied and the same FTI was used, Kelland and coworkers [12]
identified inhibition of about 60–70% in treated MCF-7 cell
line tumours. This was less than the inhibition of approximately
80% we found on the MCF-7/HER2-18 tumours, using the
same dose of R115777. This might be an indication that
HER2 expression plays a role in the response to farnesyl trans-
ferase in vivo. The effect on the HER2 transfected MCF-7 cell
line tumours was also considerably more pronounced than the
effect on the SKOV3 cell tumours, and this was also reflected
in a 10-fold lower IC50. Other studies [11,13] also were unable
to show a clear relation between markers such as growth fac-
tor receptors and ras status, and the effect of FTIs. As in the
work by Kelland and colleagues, we found no dose respond
effect with the chosen doses, namely 50 and 100 mg/kg. The
mechanism might be a threshold effect or due to saturable
drug pharmacokinetics [12].
We did not study the effect of the FTI in subgroups of DCIS
(for example, ER positive/negative or HER2 positive/negative).
We stratified by treatment dose of R115777, but it was not
possible to compare the results between the two different
doses because the number of xenografts was too small after
stratification. However, all results of proliferation and apoptotic
change in the different groups pointed in the same direction,
except for an unchanged apoptotic index after seven days of
treatment in the lower dose group.
Clinical studies of R115777 in phase I trials have shown that
a reversible myelosuppression is the dose-limiting toxicity of
the drug [35,36]. In a phase II study of continuous and inter-
mittent dosing of R15777 in women with advanced breast
cancer [37], partial response or stable disease was demon-
strated in about 20% of treated women. Forty-one of the pri-
mary tumours in the study conducted by Johnston and
coworkers [37] were analyzed for ras mutations and only one
tumour had an h-ras mutation. No correlation between
response and ER and/or HER2 expression was seen in the
study. No clinical studies involving FTIs in patients with DCIS
have been performed, and knowledge on ras status in DCIS
lesions is sparse. In one study [38] two out of 25 DCIS lesions
over-expressed wild-type k-ras, and in another study [39] four
out of five DCIS patients expressed detectable plasma levels
of wild-type ras, but no ras mutations were found in these stud-
ies.Breast Cancer Research    Vol 8 No 2    Wärnberg et al.
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We have shown that the FTI was effective in some tumours
and not in others. In the future, it might be possible to identify
those tumours that will benefit from treatment with a FTI. A
series of new signal transduction inhibitors (STIs) are under
development [40]. By gaining a better understanding of how
different interactions in normal or upregulated or downregu-
lated signal pathways work, we hopefully will be able to tailor
breast cancer treatment to individual patients. Furthermore,
data suggest that combining STIs and endocrine therapy may
be more effective than an STI alone [41-43]. There is a lack of
correlation between preclinical results with FTIs and results
from clinical studies. Inhibition of farnesylation has not been
clearly correlated to tumour inhibition in cancer patients [44].
There is a need to identify the targets of the FTIs in the preclin-
ical setting if we are to understand the clinical results and be
able to select patients in future studies. Breast cancer is
potentially a suitable tumour type for study because it is pos-
sible to perform experiments similar to ours in which human
tumours can be tested in a xenograft model.
The exact mechanism of action FTIs on cancer cells remains
unknown. Other ras-independent mechanisms of action might
play a role in the antitumour effect, including inhibition of
enzymes other than the farnesyl transferases [44,45]. We
have clearly demonstrated inhibition of farnesylation in vitro in
the present study. We also demonstrated an effect on far-
nesylation in cell tumours, with good response to R115777
treatment. However, the effect was not as clear as in the in
vitro setting and varied among the treated tumours. This indi-
cates that mechanisms other than farnesyl transferase inhibi-
tion are involved in tumour growth inhibition.
Conclusion
Treatment with the FTI reduced cell growth in vitro. Also, cell
tumour growth in vivo was reduced, and we showed
increased apoptosis and decreased proliferation, resulting in
reduced CTI. In human DCIS xenografts treatment also
resulted in a reduced CTI. The FTI R115777 is a promising
new treatment for breast cancer. The type of tumours that
respond to farnesyl transferase inhibition must be established
before the treatment can become clinically useful. We are
planning further investigations into the mechanisms of action
of the FTIs and how they affect the different pathways that reg-
ulate cell survival and proliferation.
Table 3
Results from experiments conducted in human DCIS xenografts
Index Day 0 Day 14 Day 21 Day 28
Control R115777 Control R115777 Control R115777
Overall effect
Ki67 (%) 27.1 (19.3–32.9) 9.4 (7.2–12.2) 10.3 (7.7–13.9) 13.2 (9.2–18.9) 7.5* (5.4–10.6) 11.8 (7.7–18.2) 8.4 (7.2–8.2)
Apoptosis 
(%)
3.7 (3.5–4.2) 2.8 (1.5–5.2) 3.3 (2.1–5.1) 2.7 (1.8–4.1) 3.2 (2.0–5.4) 2.5 (1.5–3.9) 3.8** (2.7–5.2)
CTI 6.2 (5.2–9.1) 2.8 (1.5–5.1) 3.5 (2.0–6.3) 6.2 (3.8–10.3) 2.6** (1.4–5.0) 3.9 (2.6–6.1) 2.4 (1.8–3.1)
R115777 100 mg/kg
Ki67 (%) 27.1 (19.3–32.9) 8.4 (5.8–12.3) 8.7 (6.1–12.3) 12.8 (7.6–21.5) 6.2*** (4.5–8.7) 12.1 (6.5–22.4) 8.7 (7.2–10.5)
Apoptosis 
(%)
3.7 (3.5–4.2) 3.3 (1.2–9.1) 3.7 (1.8–7.5) 3.0 (1.8–5.2) 3.9 (2.1–7.4) 2.9 (1.4–6.0) 4.1 (2.5–6.7)
CTI 6.2 (5.2–9.1) 1.8 (1.2–2.7) 2.5 (1.8–3.6) 4.8 (3.8–6.0) 1.9*** (1.4–2.5) 3.2 (2.5–4.1) 2.3 (1.5–3.6)
R115777 50 mg/kg
Ki67 (%) 27.1 (19.3–32.9) 11.8 (7.0–19.7) 13.9 (10.1–18.9) 14.0 (4.3–45.6) 11.1 (7.2–17.1) 11.1 (3.3–37.3) 7.9 (5.2–12.1)
Apoptosis 
(%)
3.7 (3.5–4.2) 2.1 (0.8–5.9) 2.6 (1.1–6.1) 2.3 (0.8–6.7) 2.3 (0.6–8.8) 1.9 (0.8–4.3) 3.2* (1.5–6.8)
CTI 6.2 (5.2–9.1) 5.9 (3.1–11.2) 6.1 (2.2–16.7) 9.2 (3.7–23.1) 6.2 (2.1–18.5) 6.3 (2.2–18.6) 2.4 (1.4–4.1)
The overall effect of the farnesyl transferase inhibitor R115777 on proliferation and apoptosis of ducatal carcinoma in situ (DCIS) of the breast. 
Xenografts were implanted into athymic mice on day 0 and left untreated for 14 days. Xenografts were removed on day 14, day 21, and day 28. The 
mice were gavaged twice daily with either R115777 or control vehicle starting on day 14 after removal of the first pair of xenografts. Proliferation 
was measured by immunohistochemistry (Ki67) and apoptosis by morphology on haematoxylin and eosin stained slides. Data shown represent the 
overall effect of R115777 and for both doses separately. Data only include mice for which data were available from day 14 and day 21 or day 28. 
Data are expressed as geometric means with 95% confidence intervals. Statistical significance was tested for the change between day 14 and day 
21 and between day 14 and day 28. *P < 0.05, **P < 0.01, ***P = 0.001. CTI, cell turnover index.Available online http://breast-cancer-research.com/content/8/2/R21
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